Navigation Links
Napo in Medical News

Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals

... SAN FRANCISCO, Dec. 10 /PRNewswire/ -- napo Pharmaceuticals, Inc. ("Napo") is pleased to annou... of $500,000 for the purchase of 250,000 shares of napo common stock; as well as regulatory and sales mile...llaboration Agreement) will include a reference to napo as the licensor and will include Napo's logo and r...

Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer

... napo Pharmaceuticals, Inc., which focuses on the develo...r an FDA Fast Track designation. On Jan. 16, 2007, napo met with the FDA under the Special Protocol Assess...ive design of its ADVENT trial. On March 14, 2007, napo announced it had received approval from the princi...
Napo in Medical Technology

Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera

... SAN FRANCISCO, Sept. 22 /PRNewswire/ -- napo Pharmaceuticals (LSE: NAPL/NAPU) today announces p...tic, azithromycin, and rehydration therapy. Both napo and ICDDR, B, upon receipt of additional funding, ...al Institutes of Allergy and Infectious Disease. napo is currently conducting a Phase 3 trial for crofel...

Napo Presents at ISPOR Meeting in Toronto

...um of anti-retroviral drugs. We are pleased to see napo taking the initiative to develop this new instrume...rhea." For more information please contract: napo Pharmaceuticals, Inc. Lisa Conte, Chief Executive...ector, Clinical Operations 1+ 760 918 5718 About napo Pharmaceuticals, Inc. ...

Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea

...n travelers in Mexico and Jamaica with crofelemer, napo is investigating the regulatory pathway to file an...diarrhea in people living with HIV/AIDS (CRO-HIV). napo is targeting an NDA filing for CRO-HIV around the end of the year. napo has exclusive worldwide rights to crofelemer in al...

Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea

...ritories, Glenmark will pay ascending royalties to napo on sales of crofelemer for these indications. Gl...3 2008." For more information please contact: napo Pharmaceuticals, Inc. Lisa Conte, Chief Executive... 7466 5000 Tim Anderson, Mary-Jane Johnson About napo Pharmaceuticals, Inc. ...

Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from 2006 Presented at Digestive Disease Week in Washington, D.C.

...CO, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- napo Pharmaceuticals, Inc., , which focuses on the deve... licensed crofelemer for the d-IBS indication from napo in June 2004. Trine has worldwide development and ... For more information please contact: napo Pharmaceuticals, Inc Lisa Conte, Chief Execut...
Napo in Biological Technology

Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results

...MMD trial. This was partially offset by the absence of license income from napo and the revenues lost from our withdrawal of IPLEX(TM) in the short stature...00,000 loss on investments represents the full write down on the prior year napo investment during 2008. As of December 31, 2008, we had total cash, ca...

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

...m Napo, was recorded as part of our agreement with napo in 2007. For the nine months ended September 30,...ially offset by the absence of license income from napo and the revenues lost from our withdrawal of IPLEX... investments represents the full write down of the napo investment during the first nine months of 2008. ...

Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)

...ar NEW YORK, Sept. 25 /PRNewswire-USNewswire/ -- napo Pharmaceuticals, Inc., ("Napo") of South San Franc...uch as HIV/AIDS and cholera. As part of the CAP, napo and Direct Relief International ("DRI") have formed an alliance whereby napo will provide CRO-PED at cost for distribution thro...

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008

... absence of license income from our agreement with napo Pharmaceuticals Inc., ("Napo") from which we recei...ially offset by the absence of license income from napo and the revenues lost from our withdrawal of IPLEX...ss on investments represents the write down on the napo investment during the first half of 2008. Intere...

Insmed Announces First Quarter 2008 Financial Results

...and Tercica Inc., and the absence of license income from our agreement with napo Pharmaceuticals Inc., ("Napo") from which we received a milestone payment i...y a milestone payment from Napo, was recorded as part of our agreement with napo in 2007. Interest income in the first quarter of 2008 at $279,000 was sli...

IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference

... Group Ltd. Hoersholm, Denmark Santaris BioPharmaceutical Pharmaceutical California, USA napo Pharmaceutical BioPharmaceutical Wurmlingen, Paradigm Spine, LLC Devices Germany Tokyo, Japan EyePlusPlus,...

Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results

...ng period of 2006. This increase was due to improvements in the cost recovery from our EAP and the receipt of licensing income from our agreement with napo Pharmaceuticals Inc., ("NAPO"), combined with increased sales of IPLEX(TM) during the first quarter of 2007. The net loss for the 12 months ended De...

M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer

...pany as Chief Medical Officer. Prior to joining Ocera, Dr. Harris held the position of Chief Medical Officer and Vice President of Clinical Affairs at napo Pharmaceuticals. Dr. Harris has extensive experience in gastrointestinal diseases as well as clinical and regulatory operations. "We are delighted b...
Other Tags
(Date:7/14/2014)... (PRWEB) July 14, 2014 The ... in Hicksville and Hauppauge, NY, has announced the ... long-lasting treatment for diabetic macular edema (DME) patients. ... an additional FDA-approved indication for use in diabetic ... FDA in 2009 for treatment of retinal vascular ...
(Date:7/14/2014)... 2014 There’s an old adage that says ... Lash Palette say the products offered in their preorder ... “You can reserve The Lash Palette for $40,” said Jenelle ... . , Paris explained that the first 1,000 have already ... , She went on to point out that her company ...
(Date:7/14/2014)... works could lead to the next generation of treatments ... forms when recently evolved genes are damaged, and cells ... , Astrobiologists Dr Charley Lineweaver from The Australian ... University teamed up with oncologist Dr Mark Vincent from ... model. , "The rapid proliferation of cancer cells ...
(Date:7/14/2014)... According to a new market research ... SiC, and Others), Devices (Power IC, Power Module & ... to 2014 - 2020", the Power Electronics market is ... electronics market is valued at $36.86 Billion and expected ... 2020. The report also includes an in-depth analysis of ...
(Date:7/14/2014)... may buffer some of the adverse health effects of ... researchers from the American Cancer Society, The Cooper Institute, ... the journal Mayo Clinic Proceeding s, and finds ... blood markers associated with cardiovascular disease is markedly less ... has been linked to an increase risk of obesity, ...
Breaking Medicine News(10 mins):Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 3Health News:The Lash Palette Preorder Event Has Officially Begun 2Health News:New theory turns cancer on its head 2Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 2Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 3Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 4Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 5Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... members to reduce aggression and gain access to scarce ... activities shows a certain pattern across the day. The ... Biology Letters . , Grooming between individuals in a ... To be groomed has hygienic benefits and is stress ... provide access to infants, mating opportunities and high quality ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
Other Contents